Skip to main content

Advertisement

SpringerLink
Log in

Promising systemic therapy for renal cell carcinoma

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

In the United States, advanced kidney cancer accounts for over 12,000 deaths each year. Immunotherapy with either interferon or interleukin-2 (IL-2) has been the standard of care for over two decades. High-dose IL-2 can apparently cure 10% to 15% of patients treated, but due to the required inpatient care and the attendant toxicities, it is only administered to less than 1000 patients per year in the United States (Chiron, personal communication). Interferon is a less active agent than IL-2 but it has still been shown to be superior to therapy with either megesterol or vinblastine. Interferon typically results in very few long-term responses and is given to most patients with metastatic kidney cancer. Median survival after interferon therapy is dependent on risk group but is typically 12 to 15 months. Thus, new therapies are urgently needed in this refractory disease. Novel compounds currently being tested in clinical trials are showing promise in advanced kidney cancer. The molecular targets of these drugs include interfering with the vascular endothelial growth factor receptors or the raf kinase pathway, angiogenesis inhibition, and antimicrotubule agents. A review of the preclinical and early clinical development of some of these novel compounds will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References and Recommended Reading

  1. Greenlee RT, Murray T, Bolden S, Wingo PA: Cancer statistics 2000. J Clin 2000, 50:7–33.

    CAS  Google Scholar 

  2. Shapiro JA, Williams MA, Weiss NS: Body mass index and risk of renal cell carcinoma. Epidemiology 1999, 10:188–191.

    Article  PubMed  CAS  Google Scholar 

  3. Zambrano NR, Lubensky IA, Merino MJ, et al: Histopathology and molecular genetics of renal tumors: toward unification of a classification system. J Urol 1999, 62:1246–1258.

    Google Scholar 

  4. Motzer RJ, Mazumdar M, Bacik J, et al.: Survival and prognostic stratification of 670 patients with advanced kidney carcinoma. J Clin Oncol 1999, 17:2530–2540.

    PubMed  CAS  Google Scholar 

  5. Mekhail TM, Abou-Jawde RM, BouMerhi G, et al: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005, 1:832–841.

    Article  Google Scholar 

  6. Yang JC, Sherry RM, Steinberg SM, et al: Randomized study of high-dose and low-dose Interleukin-2 in patients with metastastic renal cancer. J Clin Oncol 2003, 21:3127–3132.

    Article  PubMed  CAS  Google Scholar 

  7. Ji J, Si L, Fang W, Ling W: Interferon-gamma inhibits in situ expression of PDGF-beta mRNA by smooth muscle cells in injured rabbit arteries after transluminal balloon angioplasty. Clin Med J 2001, 114:139–142.

    CAS  Google Scholar 

  8. Medical Research Council Collaborators: Interferon-a and survival in metastatic renal cell carcinoma: early results of a randomized controlled trial. Lancet 1999, 353:14–17.

    Article  Google Scholar 

  9. Pyrhonen S, Salminen E, Ruutu M, et al: Prospective randomized trial of interferon alpha-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999, 17:2859–2867.

    PubMed  CAS  Google Scholar 

  10. Flannigan RC, Salmon SE, Blumenstein BA, et al: Nephrectomy followed by interferon alpha-2b compared with interferon alpha-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655–1659.

    Article  Google Scholar 

  11. Blankenship C, Naglich JG, Whaley JM, et al: Alternate choicec of initiation codon produces a biologically active product of the von Hippel-Lindau gene with tumor suppressor activity. Oncogene 1999,18:1529–1535.

    Article  PubMed  CAS  Google Scholar 

  12. Maxwell PPH, Wiesener MS, Chang GW, et al: The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999, 399:271–275.

    Article  PubMed  CAS  Google Scholar 

  13. Kamura T, Sato S, Iwai K, et al: Activation of HIFlalpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 2000, 97:10430–10435.

    Article  PubMed  CAS  Google Scholar 

  14. Cockman ME, Masson N, Mole DR, et al: Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000, 275:25733–25741.

    Article  PubMed  CAS  Google Scholar 

  15. Yang JC, Haworth L, Sherry RM, et al.: A randomized trial of Bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427–434. Phase II trial randomized patients to receive placebo, lowdose, or high-dose bevacizumab. The high-dose arm demon-strated a prolonged time to progression.

    Article  PubMed  CAS  Google Scholar 

  16. Drucker BJ, Schwartz L, Marion S, Motzer R: Phase II trial of ZD1839 (Iressa), an EGF receptor inhibitor, in patients with advanced renal cell carcinoma [abstract 720]. Proc ASCO 2002, 21:181a.

    Google Scholar 

  17. Dawson NA, Guo C, Zak R, et al: A phase II trial of ZD1839 in stage IV and recurrent renal cell carcinoma [abstract 1623]. Proc ASCO 2003, 22:404.

    Google Scholar 

  18. Hidalgo M: Erlotinib: preclinical investigations. Oncology 2003, 17(Suppl 12):11–16.

    PubMed  Google Scholar 

  19. Hainsworth JD, Sosman A, Spigel DR, et al.: Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC) [abstract 4502]. Proc ASCO 2004, 22:14s.

    Google Scholar 

  20. Rosen L, Mulay M, Long J, et al: Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors [abstract 765]. Proc ASCO 2003, 22:191.

    Google Scholar 

  21. Motzer RJ, Rini BI, Michaelson MD, et al: SU011248, a novel tyrosine kinase inhibitor, shows antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma: Results of a phase 2 trial [abstract 4500]. Proc ASCO 2004, 22:14s. This abstract discussed the activity of SU011248 in patients with advanced kidney cancer. The response rates and time to progression were the highest ever reported in this refractory disease.

    Google Scholar 

  22. Motzer RJ, Berg W, Ginsberg M, et al: Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002, 20:302–306.

    Article  PubMed  CAS  Google Scholar 

  23. Hernberg M, Virkkunen P, Bono P, et al: Interferon alpha-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 2003, 21:3770–3776.

    Article  PubMed  CAS  Google Scholar 

  24. Olenki T, Malhi S, Mekhail T, et al: Phase I trial of thalidomide and interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma (RCC) [abstract 1554]. Proc ASCO 2003, 22:387.

    Google Scholar 

  25. Dredge K, Marriott JB, MacDonald CD, et al: Novel thalidomide analogues display anti-angiogenic activity independent of immunomodulatory effects. Brit J Cancer 2002, 87:1166–1172.

    Article  PubMed  CAS  Google Scholar 

  26. Richardson PG, Schlossman RL, Weiler E, et al: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063–3067.

    Article  PubMed  CAS  Google Scholar 

  27. Liu Y Tohnya TM, Figg WD, et al: Phase I study of CC-5013 (Revimid), a thalidomide derivative in patients with refractory metastatic cancer [abstract 927]. Proc ASCO 2003,22:231.

    Google Scholar 

  28. Wu A, Scheffler R: Multiple-dose pharmacokinetics and safety of CC-5013 in 15 multiple myeloma patients [abstract 2056]. Proc ASCO 2004, 22:14s.

    Google Scholar 

  29. Chapa P, Rawat A, Amato RJ: Phase II study of CC-5013 in patients (pts) with renal cell cancer (RCC) [abstract 4761]. Proc ASCO 2004, 22:14s.

    Google Scholar 

  30. Chong H, Vikis HG, Guan KL: Mechanisms of regulating Raf kinase family. Cell Signal 2003, 15:463–469.

    Article  PubMed  CAS  Google Scholar 

  31. Shawver LK: Tyrosine kinase inhibitors: from the emergence of targets to their clinical development. Proc ASCO 1999, 29:45.

    Google Scholar 

  32. Davies H, Bignell GR, Cox C, et al: Mutations of B-raf in human cancer. Nature 2002, 417:949–954.

    Article  PubMed  CAS  Google Scholar 

  33. Hotte SJ, Hirte HW: BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des 2002, 8:2249–2253.

    Article  PubMed  CAS  Google Scholar 

  34. Flaherty KT, Lee RJ, Humphries R, et al: Phase I trial of BAY 43-9006 in combination with carboplatin (C) and paditaxel (P) [abstract 2854]. Proc ASCO 2003, 22:710.

    Google Scholar 

  35. Siu L, Awada A Takimoto CH, et al: Phase I study of oral raf-1 kinase inhibitor BAY 43-9006 with gemcitabine in patients with advanced solid tumors [abstract 828]. Proc ASCO 2003, 22:207.

    Google Scholar 

  36. Strumberg D, Awada A, Piccart M, et al: Final report of the phase I clinical program of the novel Raf kinase inhibitor BAY 43-9006 in patients with refractory solid tumors [abstract 813]. Proc ASCO 2003, 22:203.

    Google Scholar 

  37. Wong K-K, Eder JP, Clark J, et al.: Final results of a phase I study to determine the safety, maximum tolerated dose, pharmacokinetics and pharmacodynamics of BAY 43-9006 in repeated cycles of 1 week on / 1 week off in patients with advanced, refractory solid tumors [abstract 976]. Proc ASCO 2003, 22:244.

    Google Scholar 

  38. Ratain MJ, Flaherty KT, Stadler WM, et al: Preliminary antitumor activity of BAY 43-9006 in metastatic renal cell carcinoma and other advanced refractory solid tumors in a phase II randomized discontinuation trial (RDT) [abstract 4501]. Proc ASCO 2004, 23:381. Randomized discontinuation trial of BAY 43-9006 in advanced solid tumors. Activity in patients with advanced kidney cancer that was measured by partial responses and stable disease was observed.

    Google Scholar 

  39. Lee FY, Borzilleri R, Fairchild CR, et al.: BMS-247550: a novel epothilone analog with a mode of action similar to paditaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001, 7:1429–1437.

    PubMed  CAS  Google Scholar 

  40. Mani S, McDaid H, Hamilton A, et al: Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004, 10:1289–1298.

    Article  PubMed  CAS  Google Scholar 

  41. Burris HI, Awada A, Jones S, et al: Phase I study of the novel epothilone BMS-247550 administered weekly in patients with advanced malignancies [abstract 412]. Proc ASCO 2002, 21:104a.

    Google Scholar 

  42. Plummer R, Molife R, Verrill M, et al: Phase I and phar- macokinetic study of BMS-247550 in combination with carboplatin in patients with advanced solid malignancies [abstract 2125]. Proc ASCO 2002, 21:78b.

    Google Scholar 

  43. Mani S, McDaid H, Hamilton A, et al: Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004, 10:1289–1298.

    Article  PubMed  CAS  Google Scholar 

  44. Zhuang SH, Menefee M, Kotz H, et al: A phase II clinical trial of BMS-247550 (ixabepilone), a microtubulestabilizing agent in renal cell cancer [abstract 4550]. Proc ASCO 2004, 22:14s.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nevada Cancer Institute, University of Nevada School of Medicine, 89135, Las Vegas, NV, USA

    Nicholas J. Vogelzang MD

Authors
  1. Matthew M. Cooney MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Scot C. Remick MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicholas J. Vogelzang MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cooney, M.M., Remick, S.C. & Vogelzang, N.J. Promising systemic therapy for renal cell carcinoma. Curr. Treat. Options in Oncol. 6, 357–365 (2005). https://doi.org/10.1007/s11864-005-0039-5

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-005-0039-5

Keywords

Search

Navigation